171 related articles for article (PubMed ID: 34419592)
1. Potential application of low molecular weight excipients for amorphization and dissolution enhancement of carvedilol.
Pešić N; Dapčević A; Ivković B; Kachrimanis K; Mitrić M; Ibrić S; Medarević D
Int J Pharm; 2021 Oct; 608():121033. PubMed ID: 34419592
[TBL] [Abstract][Full Text] [Related]
2. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
3. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
4. Improving the wetting and dissolution of ibuprofen using solventless co-milling.
Varghese S; Ghoroi C
Int J Pharm; 2017 Nov; 533(1):145-155. PubMed ID: 28951348
[TBL] [Abstract][Full Text] [Related]
5. Dipeptides as co-formers in co-amorphous systems.
Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Rades T; Grohganz H
Eur J Pharm Biopharm; 2019 Jan; 134():68-76. PubMed ID: 30468836
[TBL] [Abstract][Full Text] [Related]
6. Influence of excipients in comilling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives.
Balani PN; Ng WK; Tan RB; Chan SY
J Pharm Sci; 2010 May; 99(5):2462-74. PubMed ID: 19902526
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
8. Influence of preparation technique on co-amorphization of carvedilol with acidic amino acids.
Mishra J; Löbmann K; Grohganz H; Rades T
Int J Pharm; 2018 Dec; 552(1-2):407-413. PubMed ID: 30278256
[TBL] [Abstract][Full Text] [Related]
9. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
10. Solubility and dissolution rate enhancement of ibuprofen by co-milling with polymeric excipients.
Hussain A; Smith G; Khan KA; Bukhari NI; Pedge NI; Ermolina I
Eur J Pharm Sci; 2018 Oct; 123():395-403. PubMed ID: 30076953
[TBL] [Abstract][Full Text] [Related]
11. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
[TBL] [Abstract][Full Text] [Related]
12. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
[TBL] [Abstract][Full Text] [Related]
13. Amorphization of itraconazole by inorganic pharmaceutical excipients: comparison of excipients and processing methods.
Grobelny P; Kazakevich I; Zhang D; Bogner R
Pharm Dev Technol; 2015 Jan; 20(1):118-27. PubMed ID: 25312240
[TBL] [Abstract][Full Text] [Related]
14. Functionalised calcium carbonate as a coformer to stabilize amorphous drugs by mechanochemical activation.
Liu J; Rades T; Tho I; Kissi EO
Eur J Pharm Biopharm; 2020 Oct; 155():22-28. PubMed ID: 32768607
[TBL] [Abstract][Full Text] [Related]
15. The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil.
Wlodarski K; Sawicki W; Paluch KJ; Tajber L; Grembecka M; Hawelek L; Wojnarowska Z; Grzybowska K; Talik E; Paluch M
Eur J Pharm Sci; 2014 Oct; 62():132-40. PubMed ID: 24907679
[TBL] [Abstract][Full Text] [Related]
16. Co-amorphization of atorvastatin by lisinopril as a co-former for solubility improvement.
Li W; Song J; Li J; Li M; Tian B; He Z; Liu X; Fu Q
Int J Pharm; 2021 Sep; 607():120971. PubMed ID: 34363915
[TBL] [Abstract][Full Text] [Related]
17. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
Wu W; Grohganz H; Rades T; Löbmann K
Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
[TBL] [Abstract][Full Text] [Related]
18. Co-Amorphous Combination of Nateglinide-Metformin Hydrochloride for Dissolution Enhancement.
Wairkar S; Gaud R
AAPS PharmSciTech; 2016 Jun; 17(3):673-81. PubMed ID: 26314243
[TBL] [Abstract][Full Text] [Related]
19. Influence of Co-amorphization on the Physical Stability and Dissolution Performance of an Anthelmintic Drug Flubendazole.
Vasilev NA; Voronin AP; Surov AO; Perlovich GL
Mol Pharm; 2023 Mar; 20(3):1657-1669. PubMed ID: 36732935
[TBL] [Abstract][Full Text] [Related]
20. Effects of polymer addition on the non-strongly interacting binary co-amorphous system carvedilol-tryptophan.
Wang Y; Grohganz H; Rades T
Int J Pharm; 2022 Apr; 617():121625. PubMed ID: 35259442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
